Case-control study of neuropsychiatric symptoms following COVID-19 hospitalization in 2 academic health systems

Neuropsychiatric symptoms may persist following acute COVID-19 illness, but the extent to which these symptoms are specific to COVID-19 has not been established. We utilized electronic health records across 6 hospitals in Massachusetts to characterize cohorts of individuals discharged following admission for COVID-19 between March 2020 and May 2021, and compared them to individuals hospitalized for other indications during this period. Natural language processing was applied to narrative clinical notes to identify neuropsychiatric symptom domains up to 150 days following hospitalization. Among 6,619 individuals hospitalized for COVID-19 drawn from a total of 42,961 hospital discharges, the most commonly documented symptom domains between 31 and 90 days after initial positive test were fatigue (13.4%), mood and anxiety symptoms (11.2%), and impaired cognition (8.0%). In models adjusted for sociodemographic features and hospital course, none of these were significantly more common among COVID-19 patients; indeed, mood and anxiety symptoms were less frequent (adjusted OR 0.72 95% CI 0.64-0.92). Between 91 and 150 days after positivity, most commonly-detected symptoms were fatigue (10.9%), mood and anxiety symptoms (8.2%), and sleep disruption (6.8%), with impaired cognition in 5.8%. Frequency was again similar among non-COVID-19 post-hospital patients, with mood and anxiety symptoms less common (aOR 0.63, 95% CI 0.52-0.75). Neuropsychiatric symptoms were common up to 150 days after initial hospitalization, but occurred at generally similar rates among individuals hospitalized for other indications during the same period. Post-acute sequelae of COVID-19 thus may benefit from standard if less-specific treatments developed for rehabilitation after hospitalization.

[1]  Kevin N. Heath,et al.  Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study , 2021, BMJ.

[2]  H. Holling,et al.  Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis , 2021, medRxiv.

[3]  K. Servick COVID-19 ‘brain fog’ inspires search for causes and treatments , 2021 .

[4]  D. Lazer,et al.  Comparison of post-COVID depression and major depressive disorder , 2021, medRxiv.

[5]  Paul J. Harrison,et al.  6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records , 2021, The Lancet Psychiatry.

[6]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[7]  Benjamin Bowe,et al.  High-dimensional characterization of post-acute sequelae of COVID-19 , 2021, Nature.

[8]  Guohui Fan,et al.  RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.

[9]  G. Alexopoulos,et al.  Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19 , 2020, Neuropsychopharmacology.

[10]  R. Sánchez-Valle,et al.  Presentations and mechanisms of CNS disorders related to COVID-19 , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[11]  M. Jorge Cardoso,et al.  Real-time tracking of self-reported symptoms to predict potential COVID-19 , 2020, Nature Medicine.

[12]  T. McCoy,et al.  Association between DSM-5 and ICD-11 personality dimensional traits in a general medical cohort and readmission and mortality. , 2020, General hospital psychiatry.

[13]  Tianxi Cai,et al.  High Throughput Phenotyping for Dimensional Psychopathology in Electronic Health Records , 2018, Biological Psychiatry.

[14]  M. Balas,et al.  Effectiveness and Safety of the Awakening and Breathing Coordination, Delirium Monitoring/Management, and Early Exercise/Mobility Bundle* , 2014, Critical care medicine.

[15]  Daniel Westreich,et al.  Berkson's bias, selection bias, and missing data. , 2012, Epidemiology.

[16]  Griffin M. Weber,et al.  Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) , 2010, J. Am. Medical Informatics Assoc..

[17]  Henry C. Chueh,et al.  Calculating the Benefits of a Research Patient Data Repository , 2006, AMIA.

[18]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.